Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!

To the Editor:
Data about the immunogenicity of SARS-CoV-2 vaccination in solid organ transplant recipients is lacking. This population was excluded from clinical trials and lower response to vaccination is a well-known problem in immunocompromised solid organ recipients. In this scenario, we read with great interest the article “Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients” by Rabinowich L. et al.1 recently published in Journal of Hepatology evaluating the immunogenicity of the Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in liver transplant (LT) recipients. They showed that only 47.5% of patients developed neutralizing antibody titers, 10-20 days after receiving the second dose.1 Similar results have been described in recent reports on SARS-CoV-2 vaccination in solid organ transplant recipients.2–4

We would like to share our preliminary results about a prospective study evaluating the effectiveness of SARS-CoV-2 vaccination (in terms of immunogenicity and safety) in a cohort of adult liver transplanted patients regularly followed up at 2 referral hospitals in Southern Italy (Cardarelli Hospital and Federico II Academic Hospital). All liver transplanted recipients had stable graft function prior to vaccination. Participants signed written informed consent. The study was approved by the Federico II Institutional Review Board (n. 214/2021). No patient transplanted during the COVID-19 pandemic received a liver from a SARS-CoV-2-positive donor; however, information about previous SARS-CoV-2 infection in the donors was not available.

We enrolled 365 LT patients undergoing Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccination. All patients had a negative history for COVID-19 and tested negative for anti-SARS-CoV-2 antibodies in the 7 days preceding the first dose injection. Four weeks after the second vaccine dose, blood samples were collected for analysis of anti-Spike protein IgG using LIAISON SARS-CoV-2 S1/S2-IgG chemiluminescent assay (DiaSorin, Italy) (range < 3.8 to >400 AU/ml [positive ≥25 AU/ml]). The vaccination was well tolerated, and no major adverse events occurred in

References
Author names in bold designate shared co-first authorship

[1] Guan G, Zou J, Zhang T, Lu F, Chen X. A global survey of alternative splicing of HBV transcriptome using long-read sequencing. J Hepatol 2022;76(1):234–236.

[2] Yuan S, Liao G, Zhang M, Zhu Y, Wang K, Xiao W, et al. Translational profiling reveals novel self-restricting virus-host interactions during HBV infection. J Hepatol 2021;75:74–85.

[3] Lim CS, Sozzi V, Littlejohn M, Yuen LKW, Warner N, Betz-Stablein B, et al. Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes. Microb Genom 2021;7.

[4] Kremsdorf D, Lekhaby B, Bablon P, Sotty J, Augustin J, Schuniger A, et al. Alternative splicing of viral transcripts: the dark side of the HBV. Gut 2021. https://doi.org/10.1136/gutjnl-2021-324554.

Shilin Yuan1,2
Yuedong Yang1,2
Ronggui Hu1,3,‡

1Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China
2State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China
3School of Computer Science and Engineering, Sun Yat-sen University, Guangzhou 510000, China
4School of Life Science, Hangzhou Institute for Advance Study, University of Chinese Academy of Sciences, Hangzhou 310024, China

*Corresponding author. Address: Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Hangzhou 310024, China
‡These authors contributed to this work equally.

Keywords: COVID-19; Sars-CoV-2 vaccination; liver transplantation; immunosuppression.
Received 25 June 2021; received in revised form 26 July 2021; accepted 26 July 2021; available online 3 August 2021
https://doi.org/10.1016/j.jhep.2021.07.034
any of the enrolled patients. Protective levels of antibodies were detected in 273/365 patients (74.8%) with a mean value of 214.79 ± 143 AU/ml. In the 92 patients with negative serology, statistically significant associated factors were: older age (>65 years), higher BMI, shorter time from transplantation and immunosuppressive regimens with multiple drugs and antimetabolite therapy (see Table 1 for details). These preliminary results are partially in line with Rabinowich et al. who reported negative serologic response in older patients (>63 years), those receiving a high dose of prednisone in the past 12 months, and regimens including antimetabolites and triple immunosuppressive therapy. Furthermore, we compared the serology of LT patients with a control group of 340 healthcare workers with no major comorbidities matched for age and sex (mean age 57.86 ± 8.28; 64% males). In the control group only 5/340 (1.4%) showed a negative serology 4 weeks after full vaccination, and mean antibodies levels were 314.32 ± 94.1 AU/ml, which was statistically higher than in the LT group (p < 0.0001).

Our results highlight the decreased humoral response in LT recipients. Moreover, we define the most vulnerable individuals among them (i.e., older, overweight/obese patients, and those receiving multiple drug immunosuppressive regimens and regimens including antimetabolites). Even if these findings were expected, given the known scarce antibody response to other vaccines in immunocompromised patients, we are continuing our study to obtain data about the long-term effectiveness and immunogenicity of SARS-CoV-2 vaccination and the impact of an additional dose, as recently suggested by Werbel et al.5

Authors’ contributions
M.G., I.E., V.C. made substantial contributions to the conception and the design; MG wrote the article; A.F. acquired data; FM. revised the article critically for important intellectual contribution. All authors read and approved the final version of the article.

Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhep.2021.07.034.

References
[1] Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol 2021;75(2):435–438.
[2] Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021 Jun 1;325(21):2204–2206.
[3] Malinis M, Cohen E, Azar MM. Effectiveness of SARS-CoV-2 vaccination in fully-vaccinated solid organ transplant recipients. Am J Transplant 2021 Jun 8. https://doi.org/10.1111/ajt.16713.
[4] Miele M, Busà R, Russelli G, Sorrentino MC, Di Bella M, Timoneri F, et al. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. Am J Transplant 2021 May 31. https://doi.org/10.1111/ajt.16702.
[5] Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonziku-Wang JM, et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med 2021 Jun 15. https://doi.org/10.7326/L21-0282.

Financial support
No source of funding to declare.

Conflict of interest
No personal or financial conflicts of interest for all the authors.

Please refer to the accompanying ICMJE disclosure forms for further details.

Table 1. Characteristics of LT recipients stratified according to the serologic response after 2 doses of the BioNTech BNT162b2 SARS-CoV-2 vaccine.

| Characteristics                        | Overall (n = 365) | SARS-CoV-2 seronegative (n = 92) | SARS-CoV-2 seropositive (n = 273) | p value |
|----------------------------------------|------------------|----------------------------------|-----------------------------------|---------|
| Age, years (mean ± SD)                 | 62.52 ± 12.97    | 65.01 ± 9.32                     | 61.68 ± 13.9                      | <0.0001*|
| <40 years, n (%)                       | 28 (76%)         | 1 (1.08%)                        | 27 (9.8%)                         | <0.0001**|
| 40-65 years, n (%)                     | 150 (41.1%)      | 43 (46.7%)                       | 107 (39.2%)                       | 0.071** |
| >65 years, n (%)                       | 187 (51.2%)      | 48 (52.17%)                      | 139 (50.9%)                       | 0.036** |
| Male, sex, n (%)                       | 279 (76.4%)      | 73 (79.3%)                       | 206 (75.4%)                       | 0.06**  |
| BMI, kg/m² (mean ± SD)                 | 26.56 ± 4.52     | 27.7 ± 7.09                      | 26.77 ± 4.59                      | 0.031** |
| Time from transplantation, years (mean ± SD) | 14.08 ± 8.84   | 11.94 ± 8.72                     | 14.79 ± 8.77                      | <0.001* |
| <1 year, n (%)                         | 7 (1.91%)        | 5 (5.4%)                         | 2 (0.7%)                          | <0.0001**|
| 1-5 years, n (%)                       | 69 (18.9%)       | 22 (23.9%)                       | 47 (17.21)                        | 0.0025**|
| 5-10 years, n (%)                      | 58 (15.89%)      | 15 (16.3%)                       | 43 (15.75%)                       | 0.058** |
| >10 years, n (%)                       | 231 (63.21%)     | 50 (54.3%)                       | 181 (66.3%)                       | <0.0001**|
| Immunosuppressive therapy, n (%)       |                  |                                  |                                   |         |
| Calcineurin inhibitor                  | 299 (81.9%)      | 72 (78.3%)                       | 227 (83.1%)                       | 0.19**  |
| Antimetabolite                         | 132 (36.2%)      | 49 (53.3%)                       | 83 (30.4%)                        | <0.0001**|
| mTOR inhibitor                         | 85 (23.3%)       | 30 (32.6%)                       | 55 (20.18%)                       | 0.021** |
| Single immunosuppressive agent, n (%)  | 218 (59.7%)      | 54 (59.7%)                       | 164 (59.9%)                       | <0.0001**|
| Two or more immunosuppressive agents, n (%) | 147 (40.3%)    | 58 (63.18%)                      | 89 (32.7%)                        | <0.0001**|
| Steroids, n (%)                        | 28 (7.6%)        | 9 (9.8%)                         | 19 (6.9%)                         | 0.07**  |

LT, liver transplantation.
*Kruskal-Wallis test.
**Chi squared, Fisher exact test.

1 Department of Clinical Medicine and Surgery, Gastroenterology and Hepatology Unit, University of Naples “Federico II”, Naples, Italy
2 Hepatology Unit, AORN A. Cardarelli, Naples, Italy
3 HEPATOLOGY Unit, San Filippo Neri Hospital, Rome, Italy
4 HEPATOLOGY Unit, AORN A. Cardarelli, Naples, Italy
5 HEPATOLOGY Unit, AORN A. Cardarelli, Naples, Italy

Maria Guarino1
Valentina Cossiga1
Ilaria Esposito2
Alessandro Furno3
FilocmenaMorisco1

Letters to the Editor
Reply to: “Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!”

Time for comprehensive data analysis

To the Editor:

Guarino et al. recently published data from 365 liver transplant (LT) recipients receiving 2 doses of the Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine, reporting a positive serological response rate of 74.8%.1 Earlier this year we published data showing only a 47.5% positive serological response in LT recipients following an identical vaccination protocol.2 This significant difference in outcomes requires discussion regarding the effectiveness of the SARS-CoV-2 vaccine in LT recipients.

Initial data regarding SARS-CoV-2 vaccination response in LT recipients were limited. A number of recently published studies add valuable information, with reported response rates ranging from 37.5% to 81%.3–8 Several SARS-CoV-2 vaccination studies Table 1. Summary of recently published SARS-CoV-2 2nd vaccine studies that included LT patients.

| Paper                        | Number of LT recipients | Type of SARS-CoV-2 vaccine | Positive serological response rate | Antibody titer compared to control group† | Factor related to reduced response rate |
|------------------------------|-------------------------|---------------------------|-----------------------------------|------------------------------------------|----------------------------------------|
| Guarino et al.1              | 365                     | Pfizer-BioNTech BNT162b2  | 74.8%                             | 214.79 ± 143 vs. 314.32 ± 94.1 AU/ml (p < 0.0001)†† | Age >65 yr, higher BMI, shorter time from transplantation, immunosuppressive regimens with multiple drugs, antimetabolite therapy |
| Rabinowich et al.2          | 80                      | Pfizer-BioNTech BNT162b2  | 47.5%                             | 95.41 ± 92.4 vs. 200.5 ± 65.1 AU/ml (p < 0.001)†† | Age, lower eGFR, high dose prednisone in the past 12, triple therapy immunosuppression, MMF |
| Strauss et al.3,4           | 161                     | Pfizer-BioNTech BNT162b2 Moderna mRNA-1273 | 81%                               | 81.9-250 U/ml, no control†† | Antimetabolite therapy, type of vaccine |
| Rashidi-Alavijeh et al.4    | 43                      | Pfizer-BioNTech BNT162b2  | 79%                               | 552.7 vs. >2,080 BAU/ml (p < 0.0001)†† | MMF |
| Boyarsky et al.5,6          | 129 (cohort of 658 SOT recipients) | Pfizer-BioNTech BNT162b2 Moderna mRNA-1273 | 79.8%                             | For all SOT recipients: age, type of organ, years since transplant, antimetabolite therapy, type of vaccine |
| Marion et al.6             | 58 (cohort of 367 SOT recipients) | Pfizer-BioNTech BNT162b2 Moderna mRNA-1273 | 50%                              | No clinical data |
| Mazzola et al.7             | 58 (cohort of 143 SOT recipients) | Pfizer-BioNTech BNT162b2  | 37.5%                             | For all SOT recipients: age >60 yr, type of organ, treated with corticoids, triple-therapy immunosuppression, transplanted <2 yr, diabetic patients |

eGFR, estimated glomerular filtration rate; LT, liver transplant; MMF, mycophenolate mofetil; SOT, solid organ transplant.

*Studies including LT recipients in a cohort of SOT patients.
**Patients from this study were included in a previous all organ report.
†Antibody titers provided only for studies exclusive to LT recipients.
††LIAISON SARS-CoV-2 S1/S2 IgG chemiluminescent assay (DiaSorin, Italy).
†Anti-RBD immunoassay (Roche Elecsys).

Received 16 September 2021; accepted 28 September 2021; available online 8 October 2021